NCT01617148View on ClinicalTrials.gov

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2015

Conditions
Exudative Macular Degeneration
Interventions
DRUG

Aflibercept

Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.

Trial Locations (1)

44195

Cole Eye Institute, Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Rishi Singh

OTHER

NCT01617148 - Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept | Biotech Hunter | Biotech Hunter